Open Access
Issue
BioMedicine
Volume 8, Number 2, June 2018
Article Number 8
Number of page(s) 6
DOI https://doi.org/10.1051/bmdcn/2018080208
Published online 28 May 2018

© Author(s) 2018. This article is published with open access by China Medical University

Licence Creative Commons
Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

1. Introduction

Prostate cancer has been reported with a high incidence of 7.9%, representing the fourth leading cancer in the general population, according to the International Agency for Research on Cancer (IARC) of the World Health Organization released (WHO) in 2014 [1]. In a more recent report, 26% of newly diagnosed cases of cancer in the United States and 9% of men’s deaths are related to prostate cancer [2]. In other reports, the incidence rates of prostate cancer are different in different Asian countries, ranging from low incidence (2/100,000 population in Iran) to high incidence (20/100,000 population in the Philippines). In Iran, prostate cancer is one of the most common cancers among men, with the highest prevalence in Tehran (41.2%) and comparatively lower prevalence in other large and industrial provinces (36.8%), and small towns and villages (22.1%) [3-8]. These reports suggest that prostate cancer is one of the most common causes of mortality in men, comprising an important health issue, which makes its treatment essential. However, despite the many treatments for prostate cancer, due to drug resistance, several complications of used medications and treatments, the available treatment options have not been able to reduce the survival rates of prostate cancer patients and the survival rates remain far less-than-optimal [9-12].

Given the treatments that are currently being used to fight prostate cancer and associated complications, drug resistance especially in metastatic prostate cancers, ever-increasing costs of common treatments, and the increasing incidence of prostate cancer in both developing and developed countries, it is necessary to discover newer therapeutic approaches with higher efficacy to reduce the incidence and mortality of prostate cancer. In this regard, it is necessary to find cytotoxic plants against various cancers, especially prostate cancer, which, despite lower side effects, can replace chemotherapy and difficult treatments, and also be used for treatment-resistant cases [13-17]. These plants have high levels of phytochemicals that will have many therapeutic effects [18, 19]. Iran especially Chaharmahal and Bakhtiari province is rich in medicinal plants and many medicinal plants are found only in these areas and are native to these regions and the climatic conditions of these areas have caused these plants to contain high concentrations of phytochemical compounds with various therapeutic effects.

Taken together, our aim was to investigate certain species of medicinal plants in Iran, especially those growing in Chaharmahal va Bakhtiari province in Iran, whose effects have not yet been studied on prostate cancer cell lines but they are used as anticancer agents according to public beliefs and Iranian traditional medicine books, or whose anti-inflammatory and antioxidant effects were confirmed in studies so that they may be used to produce more efficient and novel drugs to treat prostate cancer.

2. Material and methods

2.1. Plant material

The plants were collected locally in different points of Chaharmahal va Bakhtiari province in Iran in May-Sep 2015 and botanically authenticated by Dr. Shirmardi (Research Center for Agricultural & Natural Resources, Shahrekord, Iran) and Miss S. Khademian (Department of Pharmacognosy, Faculty of Pharmacy, Shiraz University of Medical Sciences). Stachys inflate, Salvia multicaulis Vahl, Hertia angustifolia, Sophora alopecuroides, Haplophyllum perforatum, Moriera spinosa Boiss., Teucrium orientale L. subsp. taylori. (Boiss.), Achillea wilhelmsii, Urtica dioica, Plantago lanceolata, Euphorbia microsciadia Boiss., Medicago sativa, Satureja bachtiarica, Acanthophyllum glandulosum Bung. ex Boiss, Onosma sericeum, Parietaria judaica, Phlomis persica, Ziziphora clinopodioides, Echinophora platyloba D.C, and Euphorbia szovitsii Fisch. & C.A.Mey included in this study.

2.2. Preparation of extracts

The herbal samples were cleaned, shade dried in, pulverized to powder in a mechanical grinder and macerated in ethanol (70%) at room temperature for 72 hours. In the next step, the hydro alcoholic extracts were concentrated by a rotary evaporator under reduced pressure. Samples were dissolved in DMSO % 0.1 (dimethyl sulfoxide, Sigma) [20-23]. Finally, extracts were diluted in RPMI 1640 at concentration of 5 mg/ml.

2.3. Cell lines and culture medium

The following cancer cell lines were used for this study: PC-3 and DU145 (prostate cancer cell lines) and HDF (Human Dermal Fibroblasts) as non-cancer cell line. Cells were obtained from National Cell Bank of Iran (Pasteur Institute, Tehran, Iran).

Cells were cultured in RPMI1640 (Roswell Park Memorial Institute medium 1640; Gibco) with 1% penicillin-streptomycin and 10% FBS (Sigma) in a humidified atmosphere with 5% Co2 at 37°C throughout the assay.

2.4. Antiproliferative assay

3-[4, 5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay (MTT assay) was used for evaluating cell viability. The cells (PC-3, DU145, and HDF) cells were seeded in 96-well plates and incubated at 37°C. After 24 h of incubation, when cells reached more than 80-90% confluence, the medium was removed and the cells were treated with fresh medium containing various concentrations of plant extracts to be tested (10 μg/ml-1 mg/ml). After 48 h, the supernatant liquids were eliminated and a medium including MTT solution (0.5 mg/ml) was added to the wells which were incubated for 4 h. In the next step, supplements were eliminated, and the formazan crystals were dissolved in DMSO. The absorbance of the plates were determined at 570 nm with a reference wavelength of 630 nm in an enzyme linked immunosorbent assay (ELISA) reader.

The percentage of inhibition was measured as [1- (optical density of test/ optical density of negative control)] × 100. The IC50 value (the concentration with 50% cell inhibition) was calculated via the graph of inhibition percentage versus different extract concentrations.

2.5. Statistical analysis

The dose-response curves of the plants were fitted by means of the computer program GraphPad Prism 6.0 (GraphPad Software, USA), and IC50 was defined by regression analysis.

3. Results

In this study, 20 species of Iranian medicinal plants were investigated. The most of the plants were from Lamiaceae family (Table 1).

Table 1

Screened medicinal plants in this study.

Anticancer activity (IC50) of the 20 medicinal plants on DU-145 and PC-3 has been shown in tables 2. Extracts with IC50>300 μg/ml in MTT assay were considered inactive.

Euphorbia szovitsii Fisch. & C.A.Mey. (Fig. 1a) had the best anticancer effect on PC-3 compared other investigated medicinal plants. Also IC50s for Urtica dioica (Fig. 1b), Euphorbia szovitsii Fisch. & C.A.Mey. and Medicago sativa (Fig. 1c) were lower amount among the examined plants on Du-145.

thumbnail Fig.1

Pictures of more effective plants.

For investigating the cytotoxicity effect of medicinal plants gathered from Chaharmahal va Bakhtiari province on normal cells we investigated the effect of ethanolic extract of effective medicinal plants on HDF cell line (Table 3). In IC50 concentration, Urtica dioica. and Euphorbia szovitsii Fisch. & C.A.Mey. don’t have any effects on HDF cells.

Table 2

Anticancer effect of the ethanolic extract of medicinal plants gathered from Chaharmahal and Bakhtiari province on prostate cancer cell lines.

IC50 determined by MTT colorimetric assay.

Table 3

Cell viability of the ethanolic extract of effective medicinal plants gathered from Chaharmahalva Bakhtiari province on HDF.

4. Discussion

According to the results of studies and also the report of IARC of the WHO in 2014 [6], despite extensive studies on the discovery of anticancer drugs, the incidence and prevalence of various cancers remain high and in many cases, drug resistance leads to lack of appropriate response; therefore, it is essential to conduct further studies and discover drugs with more potent effects that can serve as alternatives to chemical drugs and reduce the side effects of current medications and therapies. Phytotherapy is one of the approaches that have been used to treat various cancers in recent years [13-17]. In this regard, the present study was carried out to screen medicinal plant species in Iran, especially Chaharmahal and Bakhtiari province, on prostate cancer cell lines. Of the studied 20 plant species, Euphorbia szovitsii fisch & C.A.Mey and Achillea wilhelmsii exerted relatively higher anticancer effects on the PC-3 cell line and Urtica dioica, Euphorbia szovitsii Fisch. & C.A.Mey and Medicago sativa exerted comparatively more potent anticancer effects on the DU-145 cell line.

So far, the preventive and anticancer effects of many medicinal plants, as well as the effects of their derivatives on different cell lines, have been studied. In a review (2015), the effects of 34 Iranian medicinal plants tested for their anticancer effects on different cell lines and with animals and human subjects were reported [23]. U. dioica, which has been investigated for its effect on prostate cancer cell lines including LNCaP and hPCPs, is one of the plants in Iran whose effects on some prostate cancer cell lines have been studied [24]. In our study, the effect of this plant on the other two cell lines of prostate cancer, i.e. PC-3 and DU-145, was investigated. A study (2014) showed that the cytotoxic effect of aqueous U. dioica extract on LNCaP cell line is mediated by apoptosis and oxidative stress [25]. Aqueous U. dioica extract results in significant inhibition of adenosine deaminase (ADA) activity in prostate tissue [26].

Medicago sativa, as one of the other plants in our study, has good anti-proliferative activity on DU-145 cell line. In the previous study, anticancer effect of M. sativa on multidrug-resistant tumor cells lines has been reported. M. sativa could induce apoptosis in these cells lines [27]. Also some of isolated compounds from M. sativa have been indicated to have antitumor activity against different cancer cell lines such as leukemia, cervix and breast cancer [28, 29]. The results of present study and other studies that have examined the effect of U. dioica and M. sativa on cancers suggest them as effective medicinal plants in the prevention and treatment of cancers.

Thymus vulgaris, Taverniera spartea, Camellia sinensis, Ferula gummosa, Allium sativum, Curcuma longa and Zingiber officinale are other species in Iran, which are similar to the studied plants studied in the current work in terms of plant families or chemical compounds, and their anticancer effects on prostate cancer have also been investigated [30-35]. However, according to the available results, none of the plant species in Iran have yet been studied for their effects on prostate cancer cell lines (DU-145 and PC-3).

In the present study, Euphorbia szovitsii Fisch. & C.A.Mey, that is a species of the Euphorbia genus, was found to have better antitumoural effects on both prostate cancer cell lines than other plants under study. The plants from the Euphorbia genus have traditionally been used to treat inflammation and tumors [36, 37]. Besides that, cytotoxic and immunosuppressive effects have been reported for the hydroalcoholic extracts of other species of the Euphorbia genus. In addition, in recent studies, the anticancer effects of other plants of the Euphorbia genus and also their compounds, have been reported specifically on various cancer cell lines, suggesting that the plants of this genus have an acceptable anti-cancer potential [38-45]. The results of our study are in line with these studies and Euphorbia szovitsii Fisch. & C.A.Mey has an acceptable potential for anticancer effects on prostate cancer.

5. Conclusion

According to our results, E. szovitsii Fisch. & C.A.Mey. with good anti-proliferative activity on both prostate cancer cell lines and U. dioica and M. sativa with good anti-proliferative activity on DU-145 cell line can serve as an effective source of natural products to develop new anti-prostate cancer drugs.

Conflicts of interest statement

The authors declare no conflict of interest.

Acknowledgments

This study has been extracted from the PhD thesis of Majid Asadi-Samani. Shahrekord University of Medical Sciences has supported this research (Grant no. 2857); we thank all who contributed to conducting this study.

References

  1. Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer. 2014. Available in: https://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf. [Google Scholar]
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29. doi:10.3322/caac.21254. [CrossRef] [PubMed] [Google Scholar]
  3. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med. 2009; 12: 15-23. [PubMed] [Google Scholar]
  4. Onsory KH, Vahabi Barzi N, Haji Mehdi Nouri Z, Mousavi M. Frequency of polymorphism in aromatase enzyme coding gene with prostate cancer risk in north indian population. J Shahid Sadoughi Univ Med Sci. 2015; 23: 660-8. [Google Scholar]
  5. Rafiemanesh H, Rajaei-Behbahani N, Khani Y, Hosseini S, Pournamdar Z, Mohammadian-Hafshejani A, et al. Incidence trend and epidemiology of common cancers in the center of Iran. Glob J Health Sci. 2016; 8: 146-55. doi: 10.5539/gjhs.v8n3p146. [CrossRef] [Google Scholar]
  6. Parkin DM. Cancer registration in Asia in the year 2000. Past, present and future. Asian Pac J Cancer Prev. 2001; 2: 430-533. [Google Scholar]
  7. Pouresmaeili F, Hosseini SJ, Farzaneh F, Karimpour A, Azargashb E, Yaghoobi M, et al. Evaluation of environmental risk factors for prostate cancer in a population of Iranian patients. Asian Pac J cancer Prev. 2013; 15: 10603-605. [CrossRef] [Google Scholar]
  8. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer J. 2015; 136: E359-86. [CrossRef] [PubMed] [Google Scholar]
  9. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194: 1537-47. [CrossRef] [Google Scholar]
  10. Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017; 119:550-9. [CrossRef] [PubMed] [Google Scholar]
  11. He T, Mullins CD. Age-related racial disparities in prostate cancer patients: A systematic review. Ethn Health. 2017; 22: 184-95. [CrossRef] [PubMed] [Google Scholar]
  12. Graham L, Banda K, Torres A, Carver BS, Chen Y, Pisano K, et al. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018. doi: 10.1007/s10637-018-0578-9. [Google Scholar]
  13. Asadi-Samani M, Kooti W, Aslani E, Shirzad H. A systematic review of Iran's medicinal plants with anticancer effects. J Evid Based Complementary Altern Med. 2016; 21: 143-53. [CrossRef] [PubMed] [Google Scholar]
  14. Kooti W, Servatyari K, Behzadifar M, Asadi-Samani M, Sadeghi F, Nouri B, et al. Effective medicinal plant in cancer treatment, part 2: review study. J Evid Based Complementary Altern Med. 2017; 22: 982-95. [CrossRef] [PubMed] [Google Scholar]
  15. Afkhami-Ardakani M, Hassanzadeh S, Shahrooz R, Asadi-Samani M, Latifi E, Luther T. Phytotherapy and phytopharmacology for reduction of cyclophosphamide-induced toxicity in the male urinary system. J Renal Inj Prev. 2017; 6: 164-70. [CrossRef] [Google Scholar]
  16. Rahimifard M, Sadeghi F, Asadi-Samani M, Nejati-Koshki K. Effect of quercetin on secretion and gene expression of leptin in breast cancer. J Trad Chin Med. 2017; 37: 321-5. [CrossRef] [Google Scholar]
  17. Ghasemi S, Lorigooini Z. A review of significant molecular mechanisms of flavonoids in prevention of prostate cancer. J Chem Pharm Sci. 2016; 9: 3388-94. [Google Scholar]
  18. Asadi-Samani M, Bagheri N, Rafieian-Kopaei M, Shirzad H. Inhibition of Th1 and Th17 cells by medicinal plants and their derivatives: a systematic review. Phytother Res. 2017; 31: 1128-39. [CrossRef] [PubMed] [Google Scholar]
  19. Heidari-Soreshjani S, Asadi-Samani M, Yang Q, Saeedi-Boroujeni A. Phytotherapy of nephrotoxicity-induced by cancer drugs: an updated review. J Nephropathol. 2017; 6: 254-63. [CrossRef] [Google Scholar]
  20. Jadhav P, Kapoor N, Thomas B, Lal H, Kshirsagar N. Antiviral potential of selected Indian medicinal (ayurvedic) plants against herpes simplex virus 1 and 2. N Am J Med Sci. 2012; 4: 641-7. [CrossRef] [PubMed] [Google Scholar]
  21. Moradi M-T, Karimi A, Alidadi S, Hashemi L. Anti-adenovirus activity, antioxidant potential, and phenolic content of dried flower buds of Syzygium aromaticum extract in HEp2 cell line. Marmara Pharma J. 2017; 21: 852-9. [CrossRef] [Google Scholar]
  22. Moradi MT, Karimi A, Alidadi S, Ghasemi-Dehkordi P, Ghaffari-Goosheh MS. Cytotoxicity and in vitro antioxidant potential of Quercus Brantii acorn extract and the corresponding fractions. Int J Pharmacogn Phytochem Res. 2016; 8: 558-62. [Google Scholar]
  23. Foo JB, Yazan LS, Tor YS, Armania N, Ismail N, Imam MU, et al. Induction of cell cycle arrest and apoptosis in caspase-3 deficient MCF-7 cells by Dillenia suffruticosa root extract via multiple signalling pathways. BMC Complement Alterne Med. 2014; 14: 197. [CrossRef] [Google Scholar]
  24. Konrad L, Mu¨ ller HH, Lenz C, Laubinger H, Aumu¨ ller G, Lichius JJ. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med. 2000; 66: 44-7. [CrossRef] [Google Scholar]
  25. Levy A, Sivanesan D, Murugan R, Jornadal J, Quinonez Y, Jaffe M, et al. Urtica dioica Induces cytotoxicity in human prostate carcinoma LNCaP Cells: involvement of oxidative stress, mitochondrial depolarization and apoptosis. Trop J Pharm Res. 2014; 13(5): 711-7. [CrossRef] [Google Scholar]
  26. Durak I, Biri H, Devrim E, So¨zen S, Avcı A. Aqueous extract of Urtica dioica makes significant inhibition on adenosine deaminase activity in prostate tissue from patients with prostate cancer. Cancer Biol Ther. 2004; 3: 855-7. [CrossRef] [PubMed] [Google Scholar]
  27. Gatouillat G, Magid AA, Bertin E, Okiemy-Akeli MG, Morjani H, Lavaud C, et al. Cytotoxicity and apoptosis induced by alfalfa (Medicago sativa) leaf extracts in sensitive and multidrug-resistant tumor cells. Nutr Cancer. 2014; 66: 483-91. [CrossRef] [PubMed] [Google Scholar]
  28. Rosenthal GA, Nkomo P. The natural abundance of L-canavanine, an active anticancer agent, in alfalfa, medicago sativa (L.). Pharm Biol. 2000; 38: 1-6. [CrossRef] [PubMed] [Google Scholar]
  29. Avato P, Migoni D, Argentieri M, Fanizzi FP, Tava A. Activity of saponins from medicago species against Hela and MCF-7 cell lines and their capacity to potentiate cisplatin effect. Anticancer Agents Med Chem. 2017; 17: 1508-18. [CrossRef] [Google Scholar]
  30. Keramati K, Sanai K, Babakhani A, Rakhshan M, Vaezi Gh, Haeri A. Effect of hydroalcoholic extract Thymus vulgaris induced prostate cancer injection DMBA in Wistar rats. J Pazhuhesh. 2011; 35: 135-40. [Google Scholar]
  31. Khalighi-Sigaroodi F, Jeddi-Tehrani M, Ahvazi M, et al. Cytotoxicity evaluation of Taverniera spartea on human cancer cell lines. J Med Plants. 2014; 2: 114-28. [Google Scholar]
  32. Ravindranath MH, Saravanan TS, Monteclaro CC, Presser N, Ye X, Selvan SR, et al. Epicatechins purified from green tea (Camellia sinensis) differentially suppress growth of gender-dependent human cancer cell lines. Evid Based Complement Alternat Med. 2006; 3: 237-47. [CrossRef] [PubMed] [Google Scholar]
  33. Kurapati KR, Samikkannu T, Kadiyala DB, Zainulabedin SM, Gandhi N, Sathaye SS, et al. Combinatorial cytotoxic effects of Curcuma longa and Zingiber officinale on the PC-3M prostate cancer cell line. J Basic Clin Physiol Pharmacol. 2012; 23: 139-46. [CrossRef] [PubMed] [Google Scholar]
  34. Arunkumar A, Vijayababu MR, Srinivasan N, Aruldhas MM, Arunakaran J. Garlic compound, diallyl disulfide induces cell cycle arrest in prostate cancer cell line PC-3. Mol Cell Biochem. 2006; 288: 107-13. [CrossRef] [PubMed] [Google Scholar]
  35. Barthomeuf C, Lim S, Iranshahi M, Chollet P. Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cellcycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine. 2008; 15: 103-11. [CrossRef] [PubMed] [Google Scholar]
  36. Hosseini Z, Lorigooini Z, Rafieian-Kopaei M, Shirmardi HA, Solati K. A review of botany and pharmacological effect and chemical composition of Echinophora species growing in Iran. Pharmacogn Res. 2017; 9: 305. [CrossRef] [Google Scholar]
  37. Nouri A, Lorigooini Z, Asadi-Samani M, Kakian F. Review on botany, traditional uses, phytochemistry and biological activities of Euphorbia microsciadia Boiss. Int J Health Med Curr Res-IJHMCR. 2017; 2: 685-92. [Google Scholar]
  38. Amirghofran Z, Malek-hosseini S, Gholmoghaddam H, Kalalinia F. Inhibition of tumor cells growth and stimulation of lymphocytes by Euphorbia species. Immunopharmacol Immunotoxicol. 2011; 33: 34-42. [CrossRef] [PubMed] [Google Scholar]
  39. Jassbi AR. Chemistry and biological activity of secondary metabolites in Euphorbia from Iran. Phytochemistry. 2006; 67: 1977-84. [CrossRef] [PubMed] [Google Scholar]
  40. Choene M, Motadi L. Validation of the antiproliferative effects of euphorbia tirucalli extracts in breast cancer cell lines. Mol Biol. 2016; 50: 115-27. [CrossRef] [Google Scholar]
  41. Shin SY, Kim CG, Jung YJ, Jung Y, Jung H, Im J, et al. Euphorbia humifusa Willd exerts inhibition of breast cancer cell invasion and metastasis through inhibition of TNFalpha-induced MMP-9 expression. BMC Complement Altern Med. 2016; 16: 413. [CrossRef] [PubMed] [Google Scholar]
  42. Sun C, Cui H, Yang H, Du X, Yue L, Liu J, et al. Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells. Oncol Lett. 2015; 10: 1117-22. [CrossRef] [PubMed] [Google Scholar]
  43. Aghaei M, Yazdiniapour Z, Ghanadian M, Zolfaghari B, Lanzotti V, Mirsafaee V. Obtusifoliol related steroids from Euphorbia sogdiana with cell growth inhibitory activity and apoptotic effects on breast cancer cells (MCF-7 and MDA-MB231). Steroids. 2016; 115: 90-7. [CrossRef] [PubMed] [Google Scholar]
  44. Karimi A, Mohammadi-Kamalabadi M, Rafieian-Kopaei M, Amjad L, Salimzadeh I. Determination of antioxidant activity, phenolic contents and antiviral potential of methanol extract of Euphorbia spinidens Bornm (Euphorbiaceae). Trop J Pharm Res. 2016; 15: 759-64. [CrossRef] [Google Scholar]
  45. Gao S, Sun D, Wang G, Zhang J, Jiang Y, Li G, et al. Growth inhibitory effect of paratocarpin E, a prenylated chalcone isolated from Euphorbia humifusa Wild., by induction of autophagy and apoptosis in human breast cancer cells. Bioorg Chem. 2016; 69: 121-8. [CrossRef] [PubMed] [Google Scholar]

All Tables

Table 1

Screened medicinal plants in this study.

Table 2

Anticancer effect of the ethanolic extract of medicinal plants gathered from Chaharmahal and Bakhtiari province on prostate cancer cell lines.

Table 3

Cell viability of the ethanolic extract of effective medicinal plants gathered from Chaharmahalva Bakhtiari province on HDF.

All Figures

thumbnail Fig.1

Pictures of more effective plants.

In the text

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.